Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion type Assertion NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_head.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion description "[Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_provenance.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion evidence source_evidence_literature NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_provenance.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion SIO_000772 18593361 NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_provenance.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion wasDerivedFrom befree-2016 NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_provenance.
- NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_assertion wasGeneratedBy ECO_0000203 NP679629.RADaeKLLsi7t6yoEo92YxBEF1oYQ_a5vncCo_ScEsxJac130_provenance.